<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" code="A01AD" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenalin in 10 minutes or 0.3 mg in an hour for an adult </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the muscular hypotonia. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
<ATC code="C02LC01" />
<ATC code="C02LC51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for desipramine, imipramine: inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring and, if necessary, adjustment of the dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure in cases of concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
